Antifungal susceptibility of Candida spp. isolates from blood cultures in a five-year period (1997-2001);Susceptibilidad antifúngica de aislados de Candida spp. de hemocultivos en un período de cinco años (1997-2001)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 9, 2003, Pages 488-492

  Durán, María Teresa ^a   Velasco, David ^a   Canle, Delia ^a   Moure, Rita ^a   Villanueva, Rosa ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

Author keywords

Antifungal resistance; Candida; Drug resistance; Fungemia

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BLOOD CULTURE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA GUILLIERMONDII; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; CULTURE MEDIUM; DILUTION; DOSE RESPONSE; DRUG SENSITIVITY; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NEWBORN INTENSIVE CARE; NONHUMAN; YEAST;

EID: 0344872556     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052332     Document Type: Article

References (20)

1. Beck-Sagué CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the U.S., 1980-1990. J Infect Dis 1993;167:1247-51.
2. Muñoz P. Candidemia: el reto que no cesa. Rev Clin Esp 1997;197:795-7.
3. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998;31:327-32.
4. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program, SCOPE Participant Group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis 1998;30:121-9.
5. Nguyen MH, Peacock JE, Morris AJ, Tanner DC, Nguyen ML, Snydman DR, et al. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996;100:617-23.
6. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27A. Villanova, Pa, National Committee for Clinical Laboratory Standards, 1997.
7. Pfaller MA, Messer SA, Hollis RJ, Espinel-Ingroff A, Ghannoum MA, Plavan H, et al. Multisite reproducibility of MIC results by the Sensititre® YeastOne colorimetric antifungal susceptibility panel. Diagn Microbiol Infect Dis 1998;31:543-7.
8. Davey KG, Szekely A, Johnson EM, Warnock DW. Comparison of a new commercial colorimetric microdilution method with a standard method for in vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. J Antimicrob Chemother 1998;42:439-44.
9. Espinel-Ingroff A, Pfaller M, Messer SA, Knapp CC, Killian S, Norris HA, et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical Laboratory Standards M27-A Reference Method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. J Clin Microbiol 1999;37:591-5.
10. Chryssanthou E. Trends in antifungal susceptibility among swedish Candida species bloodstream isolates from 1994 to 1998: comparison of the E-test and the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A reference method. J Clin Microbiol 2001;39:4181-3.
11. Gómez J, Baños V, Simaarro E, Ruiz J, Requena L, Pérez J, et al. Fungemias nosocomiales en un hospital general: Epidemiología y factores pronóstico. Estudio prospectivo 1993-1998. Enferm Infecc Microbiol Clin 2001;19:304-7.
12. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001,39:3254-9.
13. Cuenca-Estrella M, Rodero L, García-Effrón G, Rodríguez-Tudela JL. Antifungal susceptibility of Candida spp. isolated from blood in Spain and Argentina, 1996-1999. J Antimicrob Chemother 2000;49:981-7.
14. Hernández-Sampelayo T, Navarro Gómez ML, Hernández Molina JM, Gómez Campderá JA. Importancia de las infecciones fúngicas en Pediatría. Rev Clin Esp 1997;197:60-6.
15. Pfaller MA, Diekema DJ, Jones RN, Messer SA, Hollis RJ. Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY antimicrobial surveillance program, 1997 to 2000. J Clin Microbiol 2002;40:852-6.
16. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996;9:499-511.
17. Levy I, Rubin LG, Vasishtha S, Tucci V, Sood SK. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1997;26:1086-8.
18. Espinel-Ingroff A. Clinical relevance of fungal susceptibility testing and antifungal resistance. Clin Microbiol Newsl 2000;22:137-40.
19. Lozano-Chiu M, Lancaster MV, Rex JH. Evaluation of a colorimetric method for detecting amphotericin B-resistant Candida isolates. Diagn Microbiol Infect Dis 1998;31:417-24.
20. Rodríguez-Tudela JL, Cuenca-Estrella M. Estudio multicéntrico sobre fungemias por levaduras en España (abril-junio de 1997). Rev Clin Esp 1999;199:356-61.